InhaTarget Therapeutics
PrivateLast Round
Series A
Extension
Jun 1, 2022
Total Funding Raised
$7.49M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
InhaTarget Therapeutics operates in Healthcare & Life Sciences and is based in Belgium. Its latest recorded funding round was a Series A Extension round in June 2022.
InhaTarget Therapeutics is a biotechnology company that develops innovative inhalation formulations for the treatment of severe respiratory diseases and lung cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
InhaTarget Therapeutics Comparables
Compare InhaTarget Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Quench Medical | 83% | |
| Nob Hill Therapeutics | 78% | |
| Ethris | 77% |
For institutional investors. Book with your work email.
InhaTarget Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Jun 1, 2022 | ||||
| Series A Extension | Dec 1, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
InhaTarget Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Fremoluc | Series A Extension |
| Sambrinvest | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 216% MoM.
- Jun 1, 2022
$3.48M round led by Fremoluc and Sambrinvest
For institutional investors. Book with your work email.
InhaTarget Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about InhaTarget Therapeutics's valuation, stock price, and market status.
Is InhaTarget Therapeutics a public or private company?
InhaTarget Therapeutics is a private company.
What is the current stock price of InhaTarget Therapeutics?
InhaTarget Therapeutics is a private company, so its shares have no public market price. Caplight tracks InhaTarget Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is InhaTarget Therapeutics worth (valuation)?
Valuation information for InhaTarget Therapeutics is not publicly available.
Can I buy InhaTarget Therapeutics stock?
InhaTarget Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was InhaTarget Therapeutics's last funding round?
InhaTarget Therapeutics's most recent funding round was Series A Extension on June 1, 2022.
Who are the main investors in InhaTarget Therapeutics?
Key investors in InhaTarget Therapeutics include Fremoluc, Sambrinvest.
Will InhaTarget Therapeutics IPO soon?
No public IPO plans have been announced for InhaTarget Therapeutics.
How can I track InhaTarget Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in InhaTarget Therapeutics's shares on secondary markets.